Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer

Learning Objectives After completing this course, the reader will be able to: Describe the roles of hormonal treatment, chemotherapy, and biological agents in the therapy of metastatic breast cancer patients. Explain how to select the best available treatment for a metastatic breast cancer patient....

Full description

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Ohio), 2004-01, Vol.9 (6), p.617-632
Main Authors: Bernard‐Marty, Chantal, Cardoso, Fatima, Piccart, Martine J.
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - therapeutic use
Biological therapy
Breast cancer
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Chemotherapy
Drug Administration Schedule
Drug Resistance, Neoplasm
Endocrine therapy
Estrogen Antagonists - therapeutic use
Female
Humans
Neoplasm Metastasis
Premenopause
Receptor, ErbB-2 - antagonists & inhibitors
Tailoring therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Learning Objectives After completing this course, the reader will be able to: Describe the roles of hormonal treatment, chemotherapy, and biological agents in the therapy of metastatic breast cancer patients. Explain how to select the best available treatment for a metastatic breast cancer patient. Discuss the controversies and future developments of treatment modalities for metastatic breast cancer patients. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com The management of metastatic breast cancer remains an important and controversial issue. The systemic therapy, comprising endocrine, cytotoxic and biological agents, can be administered sequentially or in combination. Few drugs or combinations provide a significant improvement in survival and, therefore, in the great majority of cases, treatment is given with a palliative intent. With the exception of first‐line therapy, for which general agreement exists, currently there is no consensual standard of care. This review will summarize the current knowledge and outline the controversial issues related to systemic therapy of metastatic breast cancer, with emphasis on treatment tailoring. The potential role of tumor molecular profile(s) in the selection of patients that could benefit the most from each strategy/agent will be discussed.
ISSN:1083-7159
1549-490X
DOI:10.1634/theoncologist.9-6-617